Contineum Therapeutics (NASDAQ:CTNM) Shares Down 5.1% – Here’s What Happened

Posted by George Bondi on Aug 31st, 2026

Contineum Therapeutics, Inc. (NASDAQ:CTNM – Get Free Report) dropped 5.1% during trading on Monday . The company traded as low as $15.99 and last traded at $16.1760. Approximately 144,073 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 323,558 shares. The stock had previously closed at $17.05.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Morgan Stanley boosted their price target on shares of Contineum Therapeutics from $14.00 to $16.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Wall Street Zen upgraded shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Contineum Therapeutics in a research report on Friday, July 17th. Finally, Royal Bank Of Canada raised their price target on shares of Contineum Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Contineum Therapeutics presently has an average rating of “Hold” and an average target price of $20.25.

View Our Latest Report on CTNM

Contineum Therapeutics Stock Performance

The company’s 50 day moving average price is $14.96 and its 200 day moving average price is $13.99. The company has a market cap of $622.99 million, a price-to-earnings ratio of -9.57 and a beta of 0.74.

Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05. As a group, analysts predict that Contineum Therapeutics, Inc. will post -1.68 EPS for the current year.

Institutional Trading of Contineum Therapeutics

Several hedge funds have recently modified their holdings of CTNM. Strs Ohio bought a new position in shares of Contineum Therapeutics in the first quarter valued at approximately $27,000. Qube Research & Technologies Ltd bought a new stake in Contineum Therapeutics during the 2nd quarter worth approximately $43,000. Marex Group plc bought a new stake in Contineum Therapeutics during the 2nd quarter worth approximately $45,000. Royal Bank of Canada increased its holdings in Contineum Therapeutics by 73.5% during the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock valued at $76,000 after purchasing an additional 2,454 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in Contineum Therapeutics during the 2nd quarter valued at $76,000.

Contineum Therapeutics Company Profile

(Get Free Report)

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.